The Lipid Management Team at ESPERION has deep and broad relationships with other industry-leading experts and businesses, enabling them to extend their impact where and when needed.
Sheldon is an accomplished leader in the cardiovascular space and brings over 25 years of leadership roles to Esperion. Most recently, he was with chief commercial officer at Portola pharmaceuticals until it was acquired by Alexion. Prior to joining Portola, Sheldon was senior vice president and head of the cardiovascular franchise for Sanofi where he led U.S. business operations and product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the Company’s cardiovascular and thrombosis franchises and led marketing for the launch of ezetimibe.
Sheldon will assume responsibility for the commercial team at Esperion.
Sheldon holds a Master of Business Administration from Monmouth University, and a Bachelor of Applied Science from Drexel University. He also completed the leadership program at The Wharton School.
Rick earned an MS in Accounting from Michigan State University and a BA, with honor, in accounting from Michigan State University. Rick is also a Certified Public Accountant.
Prior to joining ESPERION, Ken was a consultant to start-ups and mid-size companies focused on CMC strategies, NDA preparation and launch readiness.
Previously, he served as VP Manufacturing at NPS Pharmaceuticals. Prior to NPS, Ken served as VP Technical Operations at Otsuka America Pharmaceuticals for five years and was responsible for US supply chain, clinical supplies, US-CMC Development, QC and Packaging Technologies.
Before Otuska, Ken served as VP Manufacturing and Supply Chain at Cephalon. Previously, he was at BMS for seventeen years in development and manufacturing roles and at JNJ for five years.
Ken is a Pharmacist and holds a BS, MS and PhD in Pharmaceutical Sciences from Rutgers University.
Dr. Foody is a distinguished healthcare thought leader and a respected leading clinical expert, particularly in the cardiovascular industry, with over twenty-five years of experience. She has diverse and extensive experience in discovery, diligence, early and late-stage clinical research, medical affairs, and project leadership.
Dr. Foody joins Esperion after six years with Johnson & Johnson, where she served in roles of increasing responsibility within the company’s Janssen Pharmaceutical Company. Since Aug 2020, she served as Vice President and Head of Data Sciences for cardiovascular, metabolism pulmonary hypertension and Retinal therapeutic areas where she was responsible for Janssen’s data science strategy and execution. Previously, she served as Janssen’s Vice President and Compound development team leader for the Xarelto™ program working closely across the Janssen buyer alliance to execute on this multi-billion-dollar compound. Prior to that, JoAnne lead Cardiovascular Medical Affairs for Janssen.
Dr. Foody began her corporate career at Merck Research Labs, where she served as Global Director Scientific Affairs of cardiovascular and metabolism, formulating franchise strategy and leading compound candidate selection through proof of concept to clinical practice. During this time, she led multiple project teams including not only supporting Ezetimibe, but also provided leadership and strategic direction on small molecules targeting atherosclerosis, heart failure, hypertension, and pulmonary hypertension.
Dr. Foody spent over two decades in academic cardiology and is a known international expert in preventive cardiology having served as an assistant professor at Yale and an associate professor at Harvard Medical Schools. She has published extensively with over 200 peer reviewed articles, guidelines, multiple chapters and authoritative textbooks in preventive cardiology, including the highly acclaimed leading cardiovascular disease textbook Preventive Cardiology: Companion to Braunwald’s Heart Disease.
Dr. Foody is a board-certified cardiologist, a Fellow of the American Heart Association, and a Fellow of the American College of Cardiology. She received her medical degree at the Pritzker School of Medicine, University of Chicago.
Dr. Foody has responsibility for Clinical Development, Clinical Operations, Clinical Pharmacology and Pharmacokinetics, BioAnalytics, Research and Development (RnD), Pharmacovigilance/Drug Safety, International Development, Medical Affairs and Advocacy.
Ashley Hall is Chief Regulatory Officer, and has navigated successful approvals of the company’s two products, Nexletol® and Nexlizet®. Prior to joining ESPERION, Ashley was Global Regulatory Lead for Cardiovascular at Amgen and oversaw the regulatory strategy and global filings for the evolocumab program, leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering.
Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012.
Prior to joining Micromet, Ashley was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune.
Ashley held various roles of increasing responsibility in global regulatory affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company.
Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute.
Ashley earned a Juris Doctorate at the University of San Diego School of Law and a Bachelor of Science in Biochemistry and Cell Biology at the University of California San Diego.